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 27 
SUMMARY 28 
Aims: The object of this review was to collect available data on 1) adverse effects observed in humans from the 29 
intake of plant food supplements (PFS) or botanical preparations; 2) the misidentification of poisonous plants; 30 
3) interactions between PFS/botanicals and conventional drugs or nutrients.  31 
Methods: PubMed/MEDLINE and Embase were searched from database inception to June 2014, using the terms 32 
“adverse effect/s”, “poisoning/s”, “plant food supplement/s”, “misidentification/s”, and “interaction/s” in 33 
combination with the relevant plant name. All papers were critically evaluated according to the WHO 34 
Guidelines for causality assessment. 35 
Results: Data were obtained for 66 plants that are common ingredients of PFS; of the 488 papers selected, 398 36 
(81.6%) dealt with adverse effects directly associated with the botanical and 89 (18.2%) concerned interactions 37 
with conventional drugs. Only 1 case was associated with misidentification. Adverse effects were reported for 38 
39 out of the 66 botanical substances searched. Of the total references, 86.5% were associated with 14 plants, 39 
including Glycine max/soybean (19.3%), Glycyrrhiza glabra/liquorice (12.5%), Ginkgo biloba/ginkgo and 40 
Camellia sinensis/green tea (both 8.6%).  41 
Conclusions: Considering the length of time examined and the number of plants included in the review, it is 42 
remarkable that: 1) the adverse effects due to botanical ingredients were relatively infrequent, if assessed for 43 
causality; 2) the number of severe clinical reactions was very limited, but some fatal cases have been described. 44 
Data presented in this review were assessed for quality in order to make the results maximally useful for 45 
clinicians in identifying or excluding deleterious effects of botanicals. 46 
47 
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INTRODUCTION 48 
The use of food supplements is growing in both Europe and USA [1]. Food supplements can contain vitamins, 49 
minerals, botanicals, amino acids, enzymes and many other ingredients, and are marketed in a variety of forms: 50 
tablets, capsules and powders, as well as drops, beverages and energy bars.  51 
Food supplements are products intended to complement the normal diet; as they are foods and not drugs, they 52 
must not be claimed to be diagnostic, preventative or therapeutic. The wide diffusion of food supplements 53 
containing botanicals (plant food supplements, PFS) has far exceeded the availability of scientific information 54 
on their benefits, adverse effects and drug interactions. The information on benefits may be partially covered by 55 
the "tradition of use", but it is more difficult to evaluate possible adverse clinical effects due to plant properties, 56 
plant misidentification or interaction with pharmaceutical drugs or nutrients.  57 
The first difficulty in this assessment is related to the discrimination of plant food supplements from traditional 58 
herbal products, because the same ingredient/product could be sold in different countries in one or the other 59 
category, and the relevant international legislation is not harmonised. Even in the European Union there are 60 
some differences in regulatory approaches [2].  61 
Several papers have considered the adverse effects associated with botanicals, and in some cases reviewed data 62 
in a specific clinical area. A 5-year toxicological study published by Shaw et al. (1997) showed that among 1297 63 
symptomatic enquiries associated with botanicals (both food supplements and traditional remedies), there was a 64 
possible or confirmed association in 785 cases [3]. Some cases reported hepatotoxicity following the use of 65 
Chinese herbal medicine for skin disorders, allergic reactions to royal jelly and propolis and heavy metal 66 
poisoning caused by remedies from the Indian subcontinent. The conclusion by Shaw et al. was that although 67 
the overall risk to public health appeared to be low, certain groups of traditional remedies/food supplements 68 
could be associated with a number of potentially serious adverse effects.  69 
Valli and Giardina in 2002
 
[4] reviewed the adverse cardiovascular events due to herbal preparations, while 70 
Pitter et al. in 2005 [5] considered food supplements aimed at body weight reduction, and reported adverse 71 
events including hepatic injury and death after the use of some herbal food supplements. For herbal Ephedra 72 
and ephedrine-containing food supplements (now banned in most countries, including European Union and 73 
USA) an increased risk of psychiatric, autonomic or gastrointestinal adverse events and heart palpitations have 74 
been reported. 75 
A retrospective study performed by the Poison Center Surveillance Project evaluating dietary supplement-76 
related calls to the centre in 2006 showed that: 1) most supplement-related adverse events were minor; 2) of 275 77 A
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calls, two-thirds were rated as probably or possibly related to supplement use; 3) sympathomimetic toxicity was 78 
most common, with caffeine-containing products accounting for 47%, and products containing Yohimbe spp. 79 
accounting for 18% of supplement-related symptomatic cases; 4) drug–herb interaction was suspected in some 80 
cases [6]. 81 
The European Project PlantLIBRA (Plant Food Supplements: Levels of Intake, Benefit and Risk Assessment, 82 
Project n. 245199 – www.plantlibra.eu) aims to foster the safe use of food supplements containing plants or 83 
botanical preparations by increasing science-based decision-making by regulators, researchers and food chain 84 
operators. The aim of this systematic review was to summarise, and critically assess for causality, the published 85 
data on: 1) adverse effects related to PFS/botanical ingredients, 2) the misidentification of poisonous plants, and 86 
3) the interactions of PFS/botanicals with pharmaceutical drugs or nutrients. 87 
 88 
 89 
MATERIALS AND METHODS 90 
Botanical ingredients 91 
The plants included in this review were derived from a consensus among partners reached after numerous 92 
meetings in the framework of the PlantLIBRA EU project and mainly represent  93 
those most commonly used in PFS. The 66 plants included in the search are listed in Table 1. 94 
 95 
Literature Search 96 
Two of the most important scientific databases of references and abstracts on life sciences and biomedical topics, 97 
PubMed/MEDLINE and Embase, were systematically searched to create the present work. The following search 98 
strategy and selection criteria were used: data were collected from database inception to June 2014, with the 99 
terms “adverse effect/s”, “poisoning/s”, “plant food supplement/s”, “misidentification/s”, and “interaction/s” in 100 
combination with the relevant plant name. 101 
 102 
Causality assessment 103 
The assessment of reports on adverse reactions to PFS and/or their botanical ingredients was performed 104 
according to the WHO Causality Assessment Criteria as described in Table 2 [7].  105 
 106 
Online Supplementary Data 107 
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The number of papers collected during the project is very high, so that we cite only 150 papers but we offer the 108 
whole list of papers classified according to the WHO Causality Assessment Criteria as Online Supplementary 109 
Data. 110 
 111 
 112 
 113 
RESULTS AND DISCUSSION 114 
The summary of data collected from the literature and assessed according to the WHO criteria of causality is 115 
reported in Table 3. Reports of adverse effects were found for 39 out of 66 botanical ingredients searched, 116 
representing 59% of all the plants included in the database search. Of the 492 papers collected, 402 (81.7%) 117 
described cases due to adverse effects directly associated with the botanical and 89 (18.1%) to interactions with 118 
conventional drugs. Only 1 case was associated with a misidentification of the ingredient Passiflora incarnata 119 
[8]. 120 
Most events (426, or 86.6%) were associated with 14 botanical ingredients; the number of papers for each of 121 
them ranged between 13 and 95.  122 
 123 
Adverse effects due to the botanical as such or as an ingredient of PFS 124 
The distribution of adverse effects was different in relation to the plant considered; Table 4 lists the number of 125 
papers regarding specific adverse effects associated with the botanicals searched and the relative causality 126 
according to the WHO classification. Since the use of a rechallenge is rare or even ethically unacceptable, the 127 
class "Certain" and "Probable/likely" are considered together as "Certain/probable association".  128 
For the 14 most documented plants, the total number of papers was 343, but during the evaluation the causality 129 
was considered uncertain/unclassifiable in 61of them; 41.4% of all the papers were associated with only two 130 
botanicals: Glycine max (91) and Glycyrrhiza glabra (51). 131 
 132 
Adverse effects due to interaction with nutrients or conventional drugs 133 
Table 5 illustrates the papers regarding the interaction of PFS/botanicals with food, beverages or conventional 134 
drugs; assessment of causality is also reported. Of the 83 papers, 38.6% was associated with Citrus aurantium 135 
(18) and Ginkgo biloba (14). 136 A
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 137 
Form responsible for adverse effects 138 
Table 6 lists the part of plant used and the commercial form (botanical as such, PFS, food) associated with the 139 
adverse effects described. In some cases, the description of product was limited and was carefully considered in 140 
causality assessment. 141 
 142 
Case reports and side effects associated with PFS and botanical ingredients: a review of the 143 
top 14  144 
As reported above, even though 39 plants (among those searched) were associated with adverse effects, only 145 
those reported as causal in at least 10 papers (total number in Table 3) were considered in this review. As a 146 
consequence, details will be reported for only 14 plants, listed according to the alphabetical order of the Latin 147 
name. 148 
 149 
Camellia sinensis (L.) Kuntze (green tea) 150 
Numerous papers (34) have been collected on adverse effects related to C. sinensis (L.) Kuntze; 29 of them were 151 
considered sufficiently documented for causality assessment. Side effects were associated with derivatives from 152 
green tea leaves and involved mainly acute hepatotoxicity. Patients showed clinical symptoms with different 153 
severity, ranging from a mild increase of serum aminotransferase levels to fulminant hepatitis requiring liver 154 
transplantation [9-12]. 155 
The types of preparation responsible for the adverse effects, with different degrees of relationship, were plant 156 
food supplements based on green tea extracts; among them: 157 
 hydroalcoholic extract [13-15];  158 
 ethanolic extract [10,12,16];  159 
 aqueous extract of green tea, consumed as tea or in capsules [9, 11, 17].  160 
Supplements were used principally for body weight control and in one case for reducing hair loss. For tea 161 
infusion, the daily intake was from 2/3 cups up to some litres. Generally, the time of onset of the reactions 162 
ranged from 5 days to 2 years of daily consumption. Most cases were classified as "certain/probable" or 163 
"possible" when other factors could contribute to the adverse effect such  as age, concomitant pathological 164 A
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conditions, several ingredients present in the preparation. Moreover, since the substance involved in the adverse 165 
effect was not always identified, an adulteration or contamination could not be excluded. For example, in two 166 
papers, the hepatotoxicity due to two Chinese herbal supplements containing tea was attributed to the presence 167 
of N-nitroso phenfluoramine [18-19]. 168 
Adverse effects of C. sinensis seem to be modulated by various factors, and in particular by the chemical 169 
composition and the type of herbal preparations. In fact, all preparations differ in their chemical composition: 1) 170 
powdered leaves contain all the tea active components; 2) infusions and aqueous extracts contain mostly 171 
hydrophilic compounds; and 3) hydroalcoholic extracts contain both hydrophilic and lipophilic components. 172 
The components most frequently indicated as responsible for hepatotoxicity are catechins and their gallic esters. 173 
In particular, the role of EGCG (EpiGalloCatechin-3-Gallate) seems predominant, as shown also in 174 
experimental in vitro and in vivo assays (20); this conclusion could also be supported by its high concentration 175 
in green tea extracts [21]. The association seems further confirmed by the lack of known adverse effects to 176 
fermented tea (black tea), where the content of EGCG is significantly reduced. 177 
Interaction between green tea and conventional drugs was recognised in 9 papers; 3 of them with 178 
certain/probable and 6 with possible causality. Most interactions were with statins, where an increase in plasma 179 
concentration and a worsening of the related side effects, such as rhabdomyolysis, were observed [21-22]. Green 180 
tea was also responsible for interfering with a certain number of drugs such as warfarin, with inhibition of 181 
activity due to the presence of vitamin K in tea [23], or acetaminophen, with exacerbation of the hepatotoxicity 182 
[24], and other natural compounds such as lutein [21], usnic acid and guggulsterones [25] or Cassia angustifolia 183 
extract [26]. In the papers reporting interaction, aqueous and hydroalcoholic extract were the most usual forms 184 
involved. 185 
 186 
Cimicifuga racemosa (L.) Nutt (black cohosh) 187 
Papers related to C. racemosa described mainly specific adverse effects (19/23) and among them 14 were 188 
classified as "certain/probable" and 5 "possible".  189 
The cases described included:  190 
1) hepatotoxicity [27-28], with cases of autoimmune hepatitis [29] 191 
2) myopathy with severe asthenia and rhabdomyolysis [30]; 192 
3) reversible complete heart block with bradycardia [31]; 193 
4) cutaneous vasculitis [32] and cutaneous pseudolymphoma [33]. 194 A
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Adverse reactions were due to the chronic ingestion of C. racemosa extracts, as such or as an ingredient of PFS 195 
(Table 6). In the case of hepatotoxicity, the event was quickly reversible after discontinuation, except in two 196 
cases where liver transplant became necessary [27, 34], and in the case described by Lynch et al [27], the event 197 
was fatal.   198 
The possible interaction with conventional drugs is mainly based on in vitro tests, where the inhibition of 199 
CYP3A4 activity was observed [35]. 200 
 201 
Cinnamomum verum J. Prest (cinnamon) 202 
Adverse effects collected in the scientific literature for C. verum were mainly classified as events with 203 
certain/probable causality (17/23 or 73.9%). Adverse effects were mainly localised in the oral cavity and were 204 
due to the use of cinnamon-flavoured beverages, candies and chewing-gum. The most important adverse effects 205 
were:  206 
1) stomatitis with swelling and burning of lip, tongue and cheeks with a case of ulceration [36-37]; 207 
2) hyperkeratotic plaques covering most of the dorsal and lateral tongue and involving  the buccal mucosa 208 
[38]; 209 
3) allergic leukoplakia of oral mucosa [39], and contact allergy [40]; 210 
4) squamous cell carcinoma of the tongue [41]. 211 
 212 
Some contact dermatitis was experienced after consumption of cinnamon-flavoured food or solutions [42]
 
or 213 
PFS containing C. verum oil [43]. One case of intoxication was observed in a child [44].  No case of interaction 214 
with nutrients or conventional drug was found.  215 
 216 
Citrus aurantium L. (bitter orange) 217 
Specific adverse effects (7) and interaction with conventional drugs (18) have been reported.  218 
The most usual adverse reactions were in the cardiovascular system, including hypertension, tachycardia, and 219 
ventricular extrasystoles [45]. 220 
Ischaemic colitis [46], allergic bronchospasm [47] and hepatitis with massive necrosis [45] were also reported.  221 
Attempted weight loss was the most common reason for using PFS containing C. aurantium. In one case, the 222 
subject used a decoction of leaves to treat a common cold [48]. An extract of ripe or unripe fruit (usually 223 A
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unspecified) was the most usual form taken by consumers. The presence of stimulant amines, such as 224 
synephrine and octopamine, in C. aurantium explains the numerous adverse cardiovascular effects. The 225 
chemical structure of synephrine resembles that of the neurotransmitter adrenalin and of the alkaloid ephedrin, 226 
so that it acts as a sympathomimetic substance [49].  227 
When C. aurantium was used in combination with caffeine, ephedrine, yohimbine and phenylethylamine, but 228 
also thyroxine, enhancement of the adverse effects was reported: stimulant cardiovascular effects, such as 229 
tachycardia and  hypertension [50], ventricular fibrillation [51], angina [52], acute myocardial infarction [53], 230 
ischaemic stroke [54] and exercise-induced syncope [55].  231 
Less frequently described were rhabdomyolysis [45], ischaemic colitis [56]
 
and psychosis [57].  232 
Cases of adverse effects to C. aurantium were mainly classified as “possible” due to the frequent presence of 233 
accompanying conditions such as obesity, hypothyroidism, asthma, diabetes, hypertension, hyperlipidaemia, 234 
alcoholism, drug abuse, depression, anxiety, nicotine use, and dehydration.  235 
 236 
Echinacea purpurea (L.) Moench (Eastern purple coneflower) 237 
The review selected a total of 20 papers reporting adverse effects due to E. purpurea. They were mainly 238 
associated with ethanolic extracts of root and herb, but side reactions to aqueous extracts were also reported. 239 
Causality was often (10/18) defined as "unclassifiable" because of the lack of clear information on the botanical 240 
preparation, description of the adverse event, patient’s anamnesis or insufficient evidence of exposure. The lack 241 
of data could be partially explained by the fact that many adverse effects were found in papers from regulatory 242 
bodies (WHO, ADRAC, BfArM, FDA), where details on the specific E. purpurea preparation were not included.  243 
Adverse reactions were associated with both allergy and hepatic or gastrointestinal effects. Allergic reactions 244 
were mainly due to IgE-mediated hypersensitivity [58] and could be due to the known  immuno-stimulating 245 
properties of E. purpurea.  Echinacea derivatives stimulate macrophage and enhance cytokine production, 246 
which could be responsible for adverse consequences in humans [59]. Hepatotoxicity was described as an acute 247 
event with features of cholestatic autoimmune hepatitis [60], and as a case of fatal liver necrosis [61]. Other 248 
clinical manifestations probably associated with E. purpurea were:  a case of erythema nodosum [62], diarrhoea, 249 
vomiting, headache and drowsiness [63]. 250 
The possible interaction of E. purpurea with pharmaceutical drugs was considered by some authors. Gorski et al. 251 
(2004) [64]
 
considered that the observed induction of CYP3A4 activity explained the interaction of unspecified 252 
root extracts with various medications, such as tolbutamide, midazolam (oral or intravenous administration), 253 A
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dextromethorphan. Other interactions with albuterol, allopurinol, beclomethasone, dihydrocodeine, 254 
roxithromycin were evaluated as unclassifiable because of the lack of clinical details [58]. 255 
In contrast, Gurley et al. (2004) [65] found there to be no significant effect of E. purpurea on cytochromes 256 
CYP3A4, CYP1A2, CYP2E1 or CYP2D6 activity. The incongruence with the results of Gorski et al. (2004) 257 
[64]
 
is probably due to the different type of extracts used: Gorski et al. (2004) used the root extract (containing 258 
more than 1% phenols as cichoric acid, chlorogenic acid and echinacoside), while Gurley et al. (2004) [65]
 
used 259 
the whole plant extract, containing principally cichoric acid.  260 
 261 
Ginkgo biloba L. (ginkgo) 262 
The review of adverse effects associated with Ginkgo biloba produced 42 papers, 28 related to adverse effect to 263 
the plant derivative as such and 14 reporting interaction with conventional drugs. Most of them (33) were 264 
classified as events with certain/probable and possible causality.  Leaves and seeds are the parts most usually 265 
consumed, both as such (roasted or cooked seeds) and as extracts. The type of extract is normally undefined 266 
apart from the study by Yagmur et al (2005) [66], where the product is specifically indicated (EGb761). 267 
Adverse reactions are usually associated with haemorrhagic complications [67-68], with one case of a subdural 268 
haematoma [69]. The activity is probably due to the antiplatelet activity of ginkgosides, and the Ginkgolide B 269 
seems to be the main terpenoid responsible for such effects [69-70]. 270 
In some papers, other symptoms were identified: acute generalised exanthematous pustulosis [71], toxic 271 
epidermal necrolysis [72], and ventricular arrhythmia [73] or convulsions [74].  272 
An increased risk of bleeding complications was observed when G. biloba was taken concomitantly with other 273 
conventional drugs acting on coagulation, such as acetyl salicylic acid [75-76], ibuprofen [77], and warfarin [78]. 274 
A subtherapeutic level of anticonvulsants (phenytoin and valproic acid), due to an induction of the cytochrome 275 
CYP2C19 by ginkgo active compounds, was also observed in a case of fatal breakthrough seizure [79].  276 
 277 
Glycine max (L.) Merr (soybean) 278 
The review produced 95 papers reporting adverse effects associated with the consumption of Glycine max; 279 
among these, only a few (4) documented an interaction with nutrients or drugs. In particular, a decreased 280 
absorption of levothyroxine was attributed to the use of a food supplement containing soybean proteins [80], 281 
while soy milk and seaweed ingestion was associated with serious thyroid dysfunction [81]. Moreover, foods 282 
containing soybean and its isoflavones were responsible for bleeding when combined with oestradiol [82]. 283 A
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During a clinical trial studying the effect of soy isoflavones and melatonin in relieving menopausal symptoms, 284 
one patient experienced tachycardia, weight gain, insomnia, drowsiness and headache [82]. 285 
The adverse effects due to Glycine max are mainly associated with the well-known allergenic potential of this 286 
legume (30/91), which is used as an ingredient in several foods and preparations such as soy milk, paediatric 287 
formulas, lecithin, etc [83-84]. Soybean is included in the list of major allergens requiring specific labelling, and 288 
the proteins responsible for the allergic reactions have been widely studied (IUIS Allergen Nomenclature Sub-289 
Committee -  http://www.allergen.org/search.php?allergensource=Glycine+max) and identified [84]. 290 
The second most important group of side effects due to soybean derivatives is associated with the isoflavone 291 
fraction [85-86]. G. max isoflavones are frequently contained in food supplements aimed at reducing 292 
menopause-related symptoms and diseases. Side effects due to their pseudo-hormonal activity have been 293 
observed both in females and males. In particular: precocious thelarche [87], uterine fibroids [88],
 
ureteral 294 
mullerian carcinosarcoma associated with endometriosis [89], gynaecomastia [90], hypogonadism and erectile 295 
dysfunction [91], testicular cancer and reproductive disorders [85, 87]. 296 
Other case reports associated with Glycine max, with satisfactory demonstration of causality, follow: 297 
1.  gastro-intestinal adverse effects, including enterocolitis, vomiting, abdominal pain and diarrhoea, 298 
gastric cancer and hepatitis [92-95]; 299 
2.  thyroid dysfunction caused by the assumption of soybean "milk" containing high levels of iodine [96]; 300 
3.  bladder cancer [97]; 301 
4.  cases with different symptoms, such as hypophosphatemia in very-low-birth-weight infants, fatal 302 
hypernatremia, migraine, hypochloremic alkalosis, transient methemoglobinemia [98-101]. 303 
 304 
 305 
Glycyrrhiza glabra L. (liquorice) 306 
The review selected 60 papers reporting adverse reactions (specific reactions and interactions) after the 307 
consumption of liquorice. Most of them were classified as certain/probable (44), and only three were deemed 308 
"unlikely". The root is the plant part utilised; sweets, chewing gum, drinks and PFS are the most usual forms 309 
consumed but data on the preparation is not always included in papers. Most adverse events had the same 310 
symptomatic pattern, which is attributable to the biological activity of glycyrrhetic acid. Hypokalemia and 311 
hypertension are the most frequent adverse events [102-103], which can be worsened by the concomitant use of 312 A
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conventional drugs, such as bendrofluazide [104], hydrochlorothiazide [105], or other diuretics [106]. 313 
Interaction with oral contraceptives, with a similar clinical pattern (hypokalemia and water retention), has also 314 
been reported [107]. In some cases, the clinical evolution was particularly severe with rhabdomyolysis [108],
 315 
hypokalemic paralysis [109], hypokalemic encephalopathy [110],
 
and cardiac arrest [111]. 316 
The adverse effects are mainly due to the liquorice’s active compound, glycyrrhetic acid, which inhibits the 11-317 
 hydroxysteroid dehydrogenase-type 2 (11-HSDH-2) enzyme that is present in the principal cells of the 318 
cortical collecting duct. Since cortisol and aldosterone are similar steroid hormones, the enzyme is needed to 319 
inactivate cortisol before it binds the aldosterone receptor inside principal cells. When 11b-HSDH-2 is inhibited, 320 
an aldosterone-like effect is promoted, which suppresses the renin-angiotensin-aldosterone axis and causes 321 
volume expansion, hypertension, hypokalemia and metabolic alkalosis [112]. 322 
 323 
Harpagophytum procumbens  (Burch) DC (Devil’s claw) 324 
Case reports associated with this botanical mainly referred to the treatment of low back pain or arthrosis of hip 325 
and knee. All studies were classified as probable/likely and were associated with derivatives of the tuber or the 326 
whole plant (extracts or PFS, see Table 6). Acting as a COX-2 inhibitor, adverse effects associated with H. 327 
procumbens preparations, which were predictable and dose-dependent, included mainly gastrointestinal 328 
disorders [113]. Throbbing frontal headache, tinnitus, anorexia and loss of taste for food were described in one 329 
patient by Grahame and Robinson in 1981 [114]. 330 
 331 
Hypericum perforatum L. (St John’s wort) 332 
Among the 10 papers describing adverse effects associated with H. perforatum, 4 (40%) were classified as 333 
certain/probable and 6 as possible. The best described cases reported convulsions and confusion [115], manic 334 
attack [116] and hypertension with [117]
 
or without delirium [118]. Other authors described sexual dysfunction 335 
[119], serotonin-syndrome-like symptoms with anxiety, hypertension, tachycardia and nausea [120] and finally, 336 
a 5-fold increase of transaminases [121].  337 
Several authors reported clinical cases of patients suffering from adverse effects due to an interaction between H. 338 
perforatum and drugs. The events were considered certain/probable in 6 out of the 9 cases and possible in the 339 
other 3. It has been shown that there may be clinically significant drug-drug interactions between H. perforatum 340 
and substances metabolized through the CYP3A4 isozyme. Specifically, reductions in therapeutic efficacy at 341 
standard doses of important CYP3A4 substrates may be observed [122].  342 
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When H. perforatum was used in combination with drugs, reduced bioavailability was shown for the following: 343 
verapamil [123], glicazide, nifedipine, omeprazole, voriconazole, anticoagulant drugs such as phenprocoumon 344 
and warfarin, statins such as atorvastatin and simvastatin [124], talinolol [125],
 
digoxin [124, 126],
 
nevirapine 345 
[127], contraceptive drugs, cyclosporine, tacrolimus and theophylline [124, 126], loperamide together with 346 
Valeriana officinalis [128]. Other authors described an interaction with selective serotonin re-uptake inhibitors 347 
to give serotonin-syndrome [126].
 
In addition, long-term use of H.perforatum was considered responsible for 348 
adrenergic desensitisation and decreased responsiveness to vasopressors, leading to a cardiovascular collapse in 349 
a patient during anaesthesia [129]. Further interactions producing a decrease of bioavailability were suggested 350 
by Hu et al. [126] with amitriptyline, alprazolam, midazolam, fexofenadine, imatinib, irinotecan, methadone, 351 
indinavir, quazepam. 352 
 353 
Panax ginseng C.A. Meyer (ginseng) 354 
The adverse effects collected in the scientific literature for ginseng can be classified as specific effects in 11 355 
cases and as an interaction with conventional drugs in 5. 356 
Among the 11, one was classified as certain/probable and 6 as possible; the remaining 4 papers were not 357 
sufficiently documented. The part of the plant utilised is the root and little information is normally included 358 
about the method of preparation. The adverse reactions described were: stimulant effects, such as nervousness 359 
and tremor, a maniacal episode in a patient with recurrent depressive illness [130],
 
metrorrhagia [131], and 360 
allergic reactions including generalised urticarial rash and difficulty in breathing [132]. 361 
Clinical events associated with co-administration of P. ginseng with conventional drugs included interaction 362 
with: the anticoagulant drug warfarin [133], the antidepressant drugs phenelzine, [134] and clomipramine [135]
 363 
inducing manic symptoms, and the tyrosine-kinase inhibitor imatinib responsible for liver damage via an 364 
interaction with the cytochrome CYP3A4 [136].  365 
 366 
Valeriana officinalis L. (valerian) 367 
Cases were classified as specific adverse effects in 6 out of 14 papers or interaction with nutrient and 368 
conventional drugs in the remaining 8. Causality of the adverse effects was rarely documented, likewise the kind 369 
of product used by the patient. The case classified as certain/probable reported hepatotoxicity [137], including a 370 
fulminant hepatic failure [138]. 371 A
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Among the cases of interaction with conventional drugs, nutrients or food/beverages, only 4 cases were 372 
considered sufficiently documented, they reported cases of: 373 
1) hypotension due to an interaction with Matricaria chamomilla and Melissa officinalis [139]; 374 
2) hand tremor, dizziness and muscular fatigue due to co-administration with Passiflora incarnata and 375 
lorazepam [140]; 376 
3) change of mental status due to a consumption together with alcohol and Ginkgo biloba [141]; 377 
4) hepatitis due to interaction with Scutellaria lateriflor, containing alkylating agents, glycoside and 378 
volatile oils [142]. 379 
Vitex agnus castus  L. (vitex or ‘chaste tree’) 380 
Nineteen papers described adverse effects to V. agnus castus. Some of them were observed during clinical 381 
studies performed during postmarketing surveillance. This is because in several European Countries V. agnus 382 
castus is included among botanical ingredients used in traditional medicine (mainly Germany and Austria), 383 
requiring marketing authorisation. All these products contain ethanolic extracts of the fruit of V. agnus castus, 384 
and are used for premenstrual syndrome. Adverse effects reported vary widely; the most frequent and 385 
documented clinical events are:  386 
1) inter-menstrual bleeding or disorders [143-145]; 387 
2) gastrointestinal disorders with diarrhoea, persistent gastroenteritis and nausea [143, 145-146]; 388 
3) acneform facial inflammation [146]; 389 
4) headache [145]; 390 
5) weight gain 143, 145-146]; 391 
6) dizziness [143, 146]; 392 
7) allergic reactions with pruritus, erythema and gastrointestinal symptoms [144]. 393 
Other less frequent adverse effects were: arteriospasm and hepatitis [147]. 394 
Causality between plant intake and adverse effects was considered certain/probable in most cases (13/18), 395 
because the adverse effects were registered during well controlled clinical studies, and the plant was often the 396 
only “treatment” used.  397 
 398 
Vitis vinifera L. (grape) 399 
All papers collected for effects of this botanical (14) were classified as "certain/probable". Most of them can be 400 A
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considered as allergic reactions, including:  oral syndrome, urticaria, angioedema, hypotension and respiratory 401 
distress, anaphylaxis and finally exercise-induced anaphylaxis [148-150].
 
The most important allergens from 402 
grapevine are endochitinase A and B, a lipid transfer protein (LTP), and a thaumatin-like protein [149].
 
No 403 
interaction with nutrients or conventional drugs has been described. 404 
 405 
4. CONCLUSIONS 406 
 407 
At the first step in searching databases for adverse effects to the 66 botanical ingredients considered (Table 1), 408 
some thousands of papers were considered. With the application of WHO assessment criteria (Table 2), the 409 
number of papers with sufficient evidence of a causal relationship was reduced to 492 for 39 plants (see Table 410 
3). No paper describing significant adverse effects was found for the remaining 27 plants. Fourteen plants were 411 
the most frequently cited, and among them two were responsible for 32% of the adverse effects reported: 412 
1. Glycine max (soybean) was considered in 95 papers, where its role in allergic reactions and hormonal-413 
like activity was demonstrated. Both effects are well known; in fact soybean is included in the list of 414 
major food allergens and the hormonal activity of phytoestrogens is the reason that it is used in 415 
menopause. 416 
2. Glycyrrhiza glabra (liquorice) was usually responsible for hypokalemia and hypertension due to its 417 
content of glycyrrhetic acid. The hypertensive potential of liquorice and its interaction with 418 
conventional drugs are also quite well known in clinical practice. 419 
Generally speaking, we could conclude that: 420 
1. cases of adverse effects to botanicals are numerous, in term of citations by scientific literature or 421 
phytovigilance centres, but an assessment according to the WHO criteria indicates that the number of 422 
those with adequate evidence for a causal relationship is significantly less,  423 
2. given the long period of time considered and the number of plants included in the review, the 424 
occurrence of adverse effects of botanical ingredients is relatively low, 425 
3. the number of severe clinical reactions is very limited, but some fatal cases have been described, 426 
4. it is important to recognise that an underestimation is also possible, for different reasons: a) the 427 
consumer usually considers botanicals as safe products and does not report their use if they are 428 
admitted to hospital or emergency service, b) since they use PFS at their own discretion, consumers 429 A
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could avoid informing the family doctor, fearing a reprimand, c) data collected by poison centres are 430 
published only in a relatively few cases. 431 
 432 
Despite these apparently reassuring findings, we still consider it important to direct the attention of clinicians to 433 
the possibility of rare but severe adverse effects from botanical preparations or ingredients of food supplements 434 
or traditional medicines. For example, the severe hepatotoxicity of Camellia sinensis (green tea) was unknown 435 
before the product Hexolise, containing a hydroalcoholic extract was marketed and which was found to be 436 
responsible for a number of cases of acute hepatitis in France and Belgium [13, 17]. Although very rare 437 
(considering the large number of green tea consumers in the world), the severity of these reactions needs 438 
information and vigilance. 439 
Similarly Citrus aurantium, which contains adrenergic amines, must be considered a potential risk both for 440 
athletes and the general population, taking into consideration the possible abuse as a substitute for the products 441 
containing Ephedra, now banned.  442 
Data presented in this review were assessed for quality, in order to be of maximum value for clinicians and the 443 
clinical management of affected patients. 444 
 445 
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Table 1 - Plants included in the review 
Abies alba Mill. Cynara scolymus L. Ocinum basilicum L. 
Aesculus hippocastanum L. Echinacea pallida Nutt. Olea europaea L. 
Aloe ferox Mill. 
Echinacea purpurea (L.) 
Moench 
Panax ginseng C.A. Meyer 
Artemisia abrotanum L. 
Epimedium brevicornum 
Maxim/sagittatum 
Passiflora incarnata L. 
Artemisia dracunculus L. Eschscholzia californica Cham. Pelargonium sidoides DC 
Borago officinalis L. Foeniculum vulgare Mill. Peumus boldus Molina 
Boswellia serrata Roxb. ex 
Colebr. 
Ginkgo biloba L. Pimpinella anisum L. 
Calendula officinalis L. Glycine max (L.) Merr. Plantago lanceolata L. 
Camellia sinensis (L.) Kuntze Glycyrrhiza glabra L. Plantago ovata Forssk 
Carica papaya L. Grindelia robusta Nutt. 
Pseudowintera colorata (Raoul) 
Dandy 
Carum carvi L. 
Harpagophytum procumbens 
(Burch.)  DC 
Rhamnus purshiana DC 
Cassia angustifolia Vahl/ 
Cassia senna L. 
Helichrysum italicum (Roth) 
Don 
Salvia hispanica/columariae L. 
Cassia obtusifolia L./Cassia 
tora L 
Heliotropium spp. 
Serenoa repens (W Baltram) 
Small. 
Chrysanthemum balsamita (L) 
Baill 
Hibiscus sabdariffa L. Serenoa serrulata Hook f. 
Cichorium intybus L. Hippophae rhamnoides L. Silybum marianum (L.) Gaertn. 
Cimicifuga racemosa (L.) Nutt. Humulus lupulus L. Taraxacum officinale Wiggers 
Cinnamomum verum J. Presl 
(Cinnamomum zeylanicum) 
Hypericum perforatum L. Thymus serpyllum L. 
Citrus aurantium L. Lavandula angustifolia Mill. Trifolium pratense L. 
Citrus limon (L) Burm. Lycium barbarum L. Vaccinium myrtillus L. 
Citrus sinensis L. Matricaria recutita L. Valeriana officinalis L. 
Crataegus monogyna Jacq. Melissa officinalis L. Vitex agnus castus L. 
Cuminum cyminum L. Myrtus communis L. Vitis vinifera L. 
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 Table 2 - Causality categories according to WHO [7] 
Causality 
classification 
Details 
Certain a clinical event, including laboratory test abnormality, 
occurring in a plausible time relationship to drug 
administration, and which cannot be explained by concurrent 
disease or other drugs or chemicals. The response to 
withdrawal of the drugs (dechallenge) should be clinically 
plausible. The event must be definitive pharmacologically or 
phenomenologically, using a satisfactory rechallenge 
procedure if necessary 
Probably/Likely a clinical event, including laboratory test abnormality, with a 
reasonable time sequence to administration of the drug, 
unlikely to be attributed to concurrent disease or other drugs or 
chemicals, and which follows a clinically reasonable response 
on withdrawal (dechallenge). Rechallenge information is not 
required to fulfil this definition  
Possible a clinical event, including laboratory test abnormality, with a 
reasonable time sequence to administrations of the drug, but 
which could also be explained by concurrent disease or other 
drugs or chemicals. Information on drug withdrawal may be 
lacking or unclear  
Unlikely a clinical event, including laboratory test abnormality, with a 
temporal relationship to drug administration which makes a 
causal relationship improbable, and in which other drugs, 
chemicals or underlying disease provide plausible explanations 
Conditional/ 
Unclassified 
a clinical event, including laboratory test abnormality, reported 
as an adverse reaction, about which more data is essential for a 
proper assessment, or the additional data is under examination  
Unassessable/ 
unclassifiable 
a report suggesting an adverse reaction which cannot be 
judged because information is insufficient or contradictory, 
and which cannot be supplemented or verified 
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Table 3 - Number of scientific papers describing adverse effects to botanicals/PFSs, 
including misidentification and interaction with nutrient or conventional drugs 
 
Plant by scientific name  
(common name) 
Number of 
references to 
adverse effects 
as such 
Number of 
references to 
misidentification  
Number of 
references to 
interactions 
Total 
references 
Glycine max (L.) Merr  
(soybean) 
91 0 4 95 
Glycyrrhiza glabra L. 
(licorice) 
51 0 9 60 
Camellia sinensis (L.) Kuntze 
(tea) 
34 0 9 43 
Ginkgo biloba L. 
(ginkgo/Maideinhair tree)) 
28 0 14 42 
Citrus aurantium L. (bitter 
orange) 
7 0 18 25 
Cinnamomum verum J.Prest 
(C. zeylanicum) (cinnamon) 
23 0 0 23 
Cimicifuga racemosa (L.) 
Nutt (black cohosh) 
19 0 4 23 
Echinacea purpurea (L.) 
Moench (Eastern purple 
coneflower) 
18 0 2 20 
Vitex agnus castus L. 
(vitex/chaste tree) 
18 0 1 19 
Hypericum perforatum L. (St 
John's wort) 
10 0 9 19 
Panax ginseng C.A. Meyer 
(ginseng) 
11 0 5 16 
Valeriana officinalis L. 
(valerian) 
6 0 8 14 
Vitis vinifera L. (grape) 14 0 0 14 
Harpagophytum procumbens 
(Burch) DC (Devil's claw) 
13 0 0 13 
Boswellia serrata Roxb 
(Indian frankincense) 
9 0 0 9 
Serenoa repens (W Baltram) 
Small (saw palmetto) 
6 0 0 6 
Citrus sinensis (L.) Osbeck 
(sweet orange) 
5 0 0 5 
Taraxacum officinale Weber 
(dandelion) 
5 0 0 5 
Aesculus hippocastanum L. 
(horse chestnut) 
2 0 2 4 
Cassia angustifolia 
Mill/Cassia senna L. (senna) 
4 0 0 4 A
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Aloe ferox Mill. (bitter aloe) 3 0 0 3 
Melissa officinalis L. (lemon 
balm) 
3 0 0 3 
Passiflora incarnata L. 
(Passion flower) 
1 1 1 3 
Peumus boldus Molina 
(boldo) 
1 0 2 3 
Cassia obtusifolia L./Cassia 
tora L. (sickle senna/Java 
bean) 
2 0 0 2 
Foeniculum vulgare Mill 
(fennel) 
2 0 0 2 
Matricaria recutita L. 
(chamomile) 
1 0 1 2 
Ocimun basilicum L. (sweet 
basil) 
2 0 0 2 
Olea europea L. (olive) 2 0 0 2 
Silybum marianum (L.) 
Gaertn (milk thistle) 
2 0 0 2 
Borago officinalis L. 
(Borage) 
1 0 0 1 
Crataegus monogyna Jacq. 
(hawthom) 
1 0 0 1 
Cynara scolymus L. (globe 
artichoke) 
1 0 0 1 
Echinacea pallida Nutt (pale 
purple coneflower) 
1 0 0 1 
Pelargonium sidoides DC 
(Umckaloab) 
1 0 0 1 
Pimpinella anisum L. (anise) 1 0 0 1 
Plantago lanceolata L. 
(ribwort plantain) 
1 0 0 1 
Rhamnus purshiana  DC  
(cascara sagrada) 
1 0 0 1 
Trifolium pratense L. (red 
clover) 
1 0 0 1 
TOTAL 402 1 89 492 
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Table 4 - Number of papers describing specific adverse effects to the 
botanicals considered and their ranking by causality* 
 
Plant by scientific name  
(common name) 
Total 
number of 
papers 
describing 
side effects 
Papers reporting  
certain/probable 
association 
Papers 
reporting  
possible 
association 
Papers showing 
unlikely/unassessable 
association 
Glycine max (L.) Merr 
(soybean) 
91 58 11 22 
Glycyrrhiza glabra L. 
(licorice) 
51 38 11 2 
Camellia sinensis (L.) 
Kuntze (tea) 
34 15 14 5 
Ginkgo biloba L. 
(ginkgo/Maideinhair tree) 
28 19 4 5 
Cinnamomum verum J 
Presl (zeylanicum) 
(cinnamon) 
23 17 2 4 
Vitex agnus castus L. 
(vitex/chaste tree) 
18 13 1 4 
Echinacea purpurea (L.) 
Moench (Eastern purple 
coneflower) 
18 8 0 10 
Cimicifuga racemosa (L.) 
Nutt (black cohosh) 
19 14 5 0 
Vitis vinifera L. (grape) 
14 14 0 0 
Harpagophytum 
procumbens DC (Devil's 
claw) 
13 13 0 0 
Hypericum perforatum L. 
(St John's wort) 
10 4 6 0 
Panax ginseng C.A. 
Meyer (ginseng) 
11 1 6 4 
Citrus aurantium L. 
(bitter orange) 
7 5 0 2 
Valeriana officinalis L. 
(valerian) 
6 1 2 3 
TOTAL 
 
343 
 
220 
 
62 
 
61 
 
*Because of the high number of citations, the whole list of papers is organized for plant and 
causality in the Online Supplementary Data 
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Table 5 - Number of papers reporting interactions between the botanicals considered 
and nutrients, food or conventional drugs with ranking by causality* 
Plant by scientific name  
(common name) 
Total 
number of 
papers 
describing 
interactions 
Papers reporting  
certain/probable 
association 
Papers 
reporting  
possible 
association 
Papers showing 
unlikely/unassessable 
association 
Citrus aurantium L. (bitter 
orange) 
18 6 11 1 
Ginkgo biloba L. 
(ginkgo/Maideinhair tree) 
14 7 3 4 
Glycyrrhiza glabra L. 
(licorice) 
9 6 2 1 
Camellia sinensis (L.) 
Kuntze (tea) 
9 3 6 0 
Hypericum perforatum L. 
(St John's wort) 
9 6 3 0 
Valeriana officinalis L. 
(valerian) 
8 0 4 4 
Glycine max (L.) Merr 
(soybean) 
4 1 2 1 
Cimicifuga racemosa (L.) 
Nutt (black cohosh) 
4 0 4 0 
Panax ginseng C.A. Meyer 
(ginseng) 
5 1 4 0 
Echinacea purpurea (L.) 
Moench (Eastern purple 
coneflower) 
2 1 1 0 
Vitex agnus castus L. 
(vitex/chaste tree) 
1 0 0 1 
TOTAL 83 31 40 12 
 
*Because of the high number of citations, the whole list of papers is organized for plant and 
causality in the Online Supplementary Data 
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Table 6 - Form used by consumers experiencing adverse effects 
Plant by scientific name  
(common name) 
Botanical 
part used  
(when 
specified) 
Food  and 
beverages 
(functional, 
flavoured 
etc.) 
PFS 
(type) 
Other 
Camellia sinensis (L.) 
Kuntze (tea) 
Leaves 
Tea (high 
quantity) 
Capsules 
containing 
micronized leaf 
powder or 
different 
extracts 
Acqueous, 
ethanolic, 
hydroalcoholic 
extracts 
Cimicifuga racemosa (L.) 
Nutt (black cohosh) 
Rizhoma - 
Capsules 
containing 6 
plants 
including 
C.racemosa 
Standardized 
unspecified extract 
Cinnamomum verum J Presl 
(zeylanicum) (cinnamon) 
Bark 
Flavoured 
candies and 
foods; sweet 
vermouth and 
coffee 
PFS 
(containing oil) 
Oil, chewing-gum, 
toothpaste, 
mounthrinse 
Citrus aurantium L. (bitter 
orange) 
Ripe and 
unripe fruit 
Fruit rind 
- - 
Unspecified 
extracts, decoction 
Echinacea purpurea (L.) 
Moench (Eastern purple 
coneflower) 
Root or 
coneflower 
Juice  
Juice combined 
with other 
ingredients 
Hydroalcoholic, 
acquous or 
unspecified extracts 
Ginkgo biloba L. 
(ginkgo/Maideinhair tree) 
Leaves, seeds 
Roasted 
ginkgo seeds, 
microwave 
cooked seeds 
PFS containing 
extracts 
Extracts, ginkgolide 
mixtures 
Glycine max (L.) Merr 
(soybean) 
Seeds 
Soybean 
protein based 
formula, 
soybean 
"milk", Miso 
(fermented 
soybean), 
Tofu, Baloney 
(sausage) 
Supplements 
containing 
soybean 
isoflavones  
Lecithins, soybean 
protein 
concentrates, 
soybean granules, 
soybean flour 
Glycyrrhiza glabra L. 
(licorice) 
Root 
Licorice rope 
and candies, 
juices, drinks, 
Pontefract 
cake 
PFS tablets, 
"herbal tonic" 
Chewing-gum, 
decoction, 
concentrated juice 
Harpagophytum procumbens 
DC (Devil's claw) 
Tuber, root 
tuber, 
secondary 
tuber, whole 
plant 
- 
Capsules 
containing 
extract from 
whole plant 
Acqueous extract, 
ethanol extract, 
powder from root or 
secondary tubers A
cc
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d 
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Hypericum perforatum L. (St 
John's wort) 
Flowering 
herb 
- 
Tablets, 
unspecified 
preparations, 
including an 
extract 
enriched in 
hyperforin 
Unspecified extracts 
Panax ginseng C.A. Meyer 
(ginseng) 
Root 
Candies and 
teas 
Ginseng syrup 
Dry root, extracts 
(from standardized 
to unspecified), 
chewing-gum 
Valeriana officinalis L. 
(valerian) 
Root - Infusions Raw root material 
Vitex agnus castus L. 
(vitex/chaste tree) 
Fruit - - 
Ethanolic/acquous 
extracts  
Vitis vinifera L. (grape) 
Fruit and 
leaves 
Fresh and dry 
fruit,  
Juices 
- 
Acquous extract, 
hydroalcoholic 
extract; 
unspecified skin 
extract 
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